3 Value Stocks Near 52-Week Lows Worth Buying
These three value stocks may have taken it on the chin recently, but they could be poised for a quick rebound.
BioMarin Takes Aim at Sarepta
BioMarin's acquisition of Prosensa puts it in direct competition with Sarepta.
Stop Worrying About Ebola: This is a Much More Pressing Concern
Ebola may be garnering all of the headlines, but this infectious disease has been a contributing factor to the eighth leading cause of death in the U.S.
GlaxoSmithKline vs. Sanofi: Which Is The Better Dividend Stock?
Shares of healthcare giants GlaxoSmithKline and Sanofi have fallen hard this year, resulting in unusually high dividend yields for these two companies. Here is a look at which company offers the better opportunity for income investors moving forward.